ANI PHARMACEUTICALS, INC Income (Loss) from Continuing Operations, Per Basic Share
ANI PHARMACEUTICALS, INC (ANIP) reported Income (Loss) from Continuing Operations, Per Basic Share of $1.34 per share for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2016-02-23
- ANI PHARMACEUTICALS, INC income (loss) from continuing operations, per basic share for the quarter ending 2014-09-30 was $0.59, a 436.36% increase year-over-year.
- ANI PHARMACEUTICALS, INC income (loss) from continuing operations, per basic share for the quarter ending 2013-09-30 was $0.11.
- ANI PHARMACEUTICALS, INC income (loss) from continuing operations, per basic share for fiscal 2015 was $1.34, a 48.66% decline from fiscal 2014.
- ANI PHARMACEUTICALS, INC income (loss) from continuing operations, per basic share for fiscal 2014 was $2.61.
- ANI PHARMACEUTICALS, INC income (loss) from continuing operations, per basic share for fiscal 2013 was -$0.96.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|
| 2015-12-31 | $1.34 10-K · filed 2016-02-23 | ||
| 2014-12-31 | $2.61 10-K · filed 2016-02-23 | ||
| 2014-09-30 | $0.59 10-Q · filed 2014-11-10 | $0.71 10-Q · filed 2014-11-10 | |
| 2013-12-31 | -$0.96 10-K · filed 2016-02-23 | ||
| 2013-09-30 | $0.11 10-Q · filed 2014-11-10 | -$2.31 10-Q · filed 2014-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |